Multiple Sclerosis

The AJMC^® Multiple Sclerosis compendium is a comprehensive resource for clinical news and expert insights for the disabling disease that impacts the brain and spinal cord.

Latest News

Ocrelizumab is approved as an IV infusion for relapsing and primary progressive forms of MS and as a subcutaneous injection, given twice a year. | Image credit: Trsakaoe - stock.adobe.com

Real-World Discontinuations of Ocrelizumab in MS Comparable to Pivotal Trials

By AJMC Contributor

January 9th 2025

Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in pivotal clinical trials among patients with different types of multiple sclerosis (MS).

Ocrelizumab is a monoclonal antibody that targets CD20 on B cells | image credit: molekuul.be - stock.adobe.com

Subcutaneous Ocrelizumab Well Tolerated in Patients With MS

By Karen Jacobson-Sive

January 8th 2025

Patients with MS had higher odds of filling prescriptions for anticonvulsants and higher odds of filling gabapentinoids and gabapentinoids without other anticonvulsants in the years leading up to onset of MS. | Image credit: Vitalii Vodolazskyi - stock.adobe.com

Pain May Be Indicator of MS Prior to Disease Onset: Study

By AJMC Contributor

January 6th 2025

Better understanding the vascular sequelae of MS may similarly unlock predictive insights for people with MS, according to investigators. | Image credit: Elena - stock.adobe.com

Meta-Analysis: Vascular Function Worse in People With MS

By Jared Kaltwasser

January 3rd 2025

Top 5 Most-Viewed MS Content of 2024

Top 5 Most-Viewed MS Content of 2024

December 27th 2024

Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis

This video series provides an in-depth look at multiple sclerosis, covering its impact, pathophysiology, treatment strategies, unmet needs, patient satisfaction, and future research. Gain key insights into managing and understanding this condition.

This video series provides an in-depth look at multiple sclerosis, covering its impact, pathophysiology, treatment strategies, unmet needs, patient satisfaction, and future research. Gain valuable insights into managing and understanding this complex condition.

Continuing Medical Education

January 24th 2025

Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment

1.5 Credits / Cardiology, Neurology, Rare Diseases

January 24th 2025

The Role of the Specialty Pharmacist in Optimizing Treatment for Amyotrophic Lateral Sclerosis: The Impact of Early Intervention, Patient-Centered Care, and Disease-Modifying Therapies in Slowing Disease Progression

1.0 Credit / Neurology

January 24th 2025

Advancing Targeted Therapies Aimed at Smoldering Disease in Multiple Sclerosis

1.0 Credit / Immunology, Neurology

January 24th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

January 24th 2025

Overview and Burden of Migraine

0.5 Credit / Neurology

January 24th 2025

The Evolving Treatment Landscape of Migraine

0.5 Credit / Neurology

January 24th 2025

The Role of the Pharmacist Migraine Management

0.5 Credit / Neurology

More News

February 1st 2017

What We're Reading: Aetna's ACA Future, Teva Loses MS Patent, and Hawaii Saves Parts of ACA

November 14th 2016

Genes, the Environment, and Autoimmune Disease

David Hafler, MD, chairman of the Department of Neurology at the Yale School of Medicine, spoke of exciting times in the field of genome-wide association study-specifically speaking to neurology, genetics, the environment, and the autoimmune response.

November 11th 2016

AJMC in the Press, November 11, 2016

A review of our peer-reviewed research in the healthcare and mainstream press.

October 26th 2016

Reconsidering the Economic Value of Multiple Sclerosis Therapies

Tiffany Shih, PhD Craig Wakeford, MA Dennis Meletiche, PharmD Jesse Sussell, PhD Adrienne Chung, PhD Yanmei Liu, MS Jin Joo Shim, MS Darius Lakdawalla, PhD

Availability of multiple sclerosis (MS) therapies provides substantial value to the currently healthy (who may contract MS in the future), particularly when treatment is fully covered by insurance.

October 11th 2016

OOP Expenses Remain a Problem in Medicare, Especially for Beneficiaries Taking Specialty Drugs

Medicare beneficiaries still face huge out-of-pocket expenses because of uncapped cost sharing in the catastrophic coverage phase. This is especially true for beneficiaries who take specialty drugs.

June 1st 2016

Current and Emerging Treatment of Multiple Sclerosis

Felecia M. Hart, PharmD Jacquelyn Bainbridge, BSPharm, PharmD

May 31st 2016

Cost-Effectiveness of Disease- Modifying Therapies in Multiple Sclerosis: A Managed Care Perspective

May 31st 2016

Economic Burden of Multiple Sclerosis and the Role of Managed Care Organizations in Multiple Sclerosis Management

Gary M. Owens, MD

May 13th 2016

Significant Toxicity of Mitoxantrone in Patients With Multiple Sclerosis: Cancer

Surabhi Dangi-Garimella, PhD

Researchers in Germany have discovered that mitoxantrone-used to treat aggressive, relapsing, or progressive multiple sclerosis-can increase the risk of leukemia and colorectal cancer in those being treated.

Two Drugs Dr Aimee Tharaldson Is Watching Closely in 2016

April 21st 2016

Two Drugs Dr Aimee Tharaldson Is Watching Closely in 2016

Aimee Tharaldson, PharmD, senior clinical consultant of emerging therapies at Express Scripts, outlined the 2 pipeline drugs she is keeping a close eye on in 2016: both are breakthrough therapies and one could have a significant impact on the market.

March 18th 2016

The MS Center of Saint Louis: A Practice Perspective of the Impacts of High Cost Sharing

Katherine Upshur, MSW, LCSW

This case study from the MS Center of Saint Louis examines how patients are impacted by high healthcare costs and addresses potential solutions to this problem.

March 17th 2016

Impact of Cost Sharing on Specialty Drug Utilization and Outcomes: A Review of the Evidence and Future Directions

Jalpa A. Doshi, PhD Pengxiang Li, PhD Vrushabh P. Ladage, BS Amy R. Pettit, PhD Erin A. Taylor, PhD, MSPH

The authors review published evidence regarding associations between high cost sharing for specialty pharmaceuticals indicated for rheumatoid arthritis, multiple sclerosis, and cancer, and their utilization.

April 18th 2015

First Generic Version of MS Drug Copaxone Approved

After months of anticipation, the FDA has approved a generic version of Copaxone, which means Momenta Pharmaceuticals and Sandoz can now sell a knockoff of a drug that generated more than $3.1 billion in sales in the US last year.

January 1st 2015

Implications for Multiple Sclerosis in the Era of the Affordable Care Act: The Shifting Managed Care Landscape

A. Scott Mathis, PharmD Gary M. Owens, MD

December 28th 2014

Implications for Multiple Sclerosis in the Era of the Affordable Care Act: An Evolving Treatment Paradigm

Luigi Brunetti, PharmD, MPH Samuel F. Hunter, MD, PhD

December 28th 2014

Implications for Multiple Sclerosis in the Era of the Affordable Care Act: A Clinical Overview

Megan Maroney, PharmD, BCPP Samuel F. Hunter, MD, PhD

December 16th 2014

Participating Faculty: Implications for Multiple Sclerosis in the Era of the Affordable Care Act: A Clinical and Managed Care Perspective [CME/CPE]

Dr Paul Wicks Points to the Benefits of Technology in MS Research

September 13th 2014

Dr Paul Wicks Points to the Benefits of Technology in MS Research

Paul Wicks, PhD, vice president of innovation at PatientsLikeMe, discussed the benefits of using technology in multiple sclerosis research by patients, providers, researchers, and other decision-makers.

Making Treatment Decisions When There Is an Abundance of Options

September 13th 2014

Making Treatment Decisions When There Is an Abundance of Options

Laura Joszt, MA

Despite the benefit of having more choices than ever before to treat patients with multiple sclerosis, the abundance of options has led to more complexity, according to speakers at the 2014 ACTRIMS-ECTRIMS Joint Meeting in Boston, Massachusetts.

The Power of Treating Patients as Partners in MS Clinical Research

September 13th 2014

The Power of Treating Patients as Partners in MS Clinical Research

Laura Joszt, MA

As a medium, the Internet neither helps nor harms in multiple sclerosis care - what matters is how clinicians and patients engage in that medium, according to Paul Wicks, PhD, vice president of innovation at PatientsLikeMe.

Dr Alasdair Coles on the Effectiveness of Alemtuzumab in Treating MS

September 12th 2014

Dr Alasdair Coles on the Effectiveness of Alemtuzumab in Treating MS

At this year's ECTRIMS conference in Boston, Alasdair Coles, MD, University of Cambridge, discussed alemtuzumab and its effectiveness in treating multiple sclerosis.

Genzyme's Lemtrada Reports Positive Results After 4 Years

September 12th 2014

Genzyme's Lemtrada Reports Positive Results After 4 Years

Laura Joszt, MA

The second year of the extension study of Lemtrada (alemtuzumab) for multiple sclerosis reported positive interim results with 70% of patients not requiring a third course of treatment.

Improving Patient-Clinician Communication and Treatment Adherence

September 12th 2014

Improving Patient-Clinician Communication and Treatment Adherence

Laura Joszt, MA

Although there have been significant advances in multiple sclerosis management, patient preferences need to be taken into account before choosing treatment, according to speakers at the 2014 ACTRIMS-ECTRIMS Joint Meeting in Boston, Massachusetts.

Engaging Patients in Their Own Treatment Decisions

September 12th 2014

Engaging Patients in Their Own Treatment Decisions

Laura Joszt, MA

Patients with multiple sclerosis want to be actively engaged in their treatment decisions, which will help their long-term health and medication adherence, according to speakers at the 2014 ACTRIMS-ECTRIMS Joint Meeting in Boston, Massachusetts.

Heterogeneity of MS Makes New Disease Biomarker Discovery Difficult

September 12th 2014

Heterogeneity of MS Makes New Disease Biomarker Discovery Difficult

Laura Joszt, MA

The treatment landscape for multiple sclerosis continues to get more complex month to month, which makes biomarker discovery increasingly important for treating the disease, said Suhayl Dhib-Jalbut, MD, professor at the Rutgers University Robert Wood Johnson Medical School, during his session at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts.

PML is Treatable in MS, but Long-Term Function Can Remain Affected

September 11th 2014

PML is Treatable in MS, but Long-Term Function Can Remain Affected

Laura Joszt, MA

Although the survival rate of natalizumab-associated progressive multifocal leukoencephalopathy (PML) is better than PML in HIV patients, long-term they may need some assistance and care, Ralf Gold, Ruhr University Bochum in Germany, said at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts.

Using Advanced Imaging Techniques to Better Understand MS Progression

September 11th 2014

Using Advanced Imaging Techniques to Better Understand MS Progression

Laura Joszt, MA

Advanced imaging techniques are becoming necessary to further understanding of the progression of multiple sclerosis, according to presenters at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts, from September 10-13.

Collaborative Decision Making Tops Efficacy for MS Patients

September 11th 2014

Collaborative Decision Making Tops Efficacy for MS Patients

Laura Joszt, MA

When choosing treatment for a patient, whether he or she has a clinically isolated syndrome or clinically definite multiple sclerosis, providers need to establish a collaborative relationship, according to speakers at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts.

April 16th 2014

The Burden of Soaring Prices of Specialty Drugs

Even as the cost of prescription drugs has plummeted for many Americans, a small slice of the population is being asked to shoulder more and more of the cost of expensive treatments for diseases like cancer and hepatitis C, according to a report to be released on Tuesday by a major drug research firm.

March 3rd 2014

Chronically Ill Face High Out-of-Pocket Costs

Those with chronic illnesses such as leukemia, hepatitis C, and multiple sclerosis may face a significant increase in their out-of-pocket expenses for specialty drugs. This is because payers are replacing fixed-dollar copayments with coinsurance rates that require patients to contribute a higher percentage of the cost for their specialty medications.

...

13 14 15 16 17 18 19 20 21 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions